nach oben

Abdominal Radiology

Erschienen in:

25.08.2018 | Pictorial essay

Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation

verfasst von: Hsien Min Low, Jin Young Choi, Cher Heng Tan

Erschienen in: Abdominal Radiology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is a unique tumor because it is one of the few cancers which can be treated based on imaging alone. Magnetic resonance imaging (MRI) carries higher sensitivity and specificity for the diagnosis of HCC than either computed tomography (CT) or ultrasound. MRI is imaging modality of choice for the evaluation of complex liver lesions and HCC because of its inherent ability to depict cellularity, fat, and hepatocyte composition with high soft tissue contrast. The imaging features of progressed HCC are well described. However, many HCC tumors do not demonstrate classical imaging features, posing a diagnostic dilemma to radiologists. Some of these can be attributed to variations in tumor biology and histology, which result in radiological features that differ from the typical progressed HCC. This pictorial review seeks to demonstrate the appearance of different variants of HCC on MRI imaging, in relation to their histopathologic features.

Jemal A, Bray F, Center MM, et al. (2011) Global cancer statistics. CA 61(2):69–90. https://doi.org/10.3322/caac.20107 PubMedCrossRef

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45(4):529–538. https://doi.org/10.1016/j.jhep.2006.05.013 PubMedCrossRef

Tan CH, Thng CH, Low AS, et al. (2011) Wash-out of hepatocellular carcinoma: quantitative region of interest analysis on CT. Ann Acad Med Singapore 40(6):269–275PubMed

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022. https://doi.org/10.1002/hep.24199 PubMedPubMedCentralCrossRef

Forner A, Vilana R, Ayuso C, et al. (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1):97–104. https://doi.org/10.1002/hep.21966 PubMedCrossRef

Marrero JA, Hussain HK, Nghiem HV, et al. (2005) Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 11(3):281–289. https://doi.org/10.1002/lt.20357 PubMedCrossRef

European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943. https://doi.org/10.1016/j.jhep.2011.12.001 CrossRef

American College of Radiology (2014) Liver Imaging and Reporting System version 2014. Accessed 1 May 2017

Rosenkrantz AB, Campbell N, Wehrli N, Triolo MJ, Kim S (2015) New OPTN/UNOS classification system for nodules in cirrhotic livers detected with MR imaging: effect on hepatocellular carcinoma detection and transplantation allocation. Radiology 274(2):426–433. https://doi.org/10.1148/radiol.14140069 PubMedCrossRef

10.

Kudo M, Matsui O, Izumi N, et al. (2014) JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 3(3–4):458–468. https://doi.org/10.1159/000343875 PubMedPubMedCentralCrossRef

11.

Lee JM, Park JW, Choi BI (2014) 2014 KLCSG-NCC Korea Practice Guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm. Dig Dis 32(6):764–777. https://doi.org/10.1159/000368020 PubMedCrossRef

12.

Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7(8):448–458. https://doi.org/10.1038/nrgastro.2010.100 PubMedPubMedCentralCrossRef

13.

Lai CL, Ratziu V, Yuen MF, Poynard T (2003) Viral hepatitis B. Lancet 362(9401):2089–2094. https://doi.org/10.1016/S0140-6736(03)15108-2 PubMedCrossRef

14.

Omata M, Cheng AL, Kokudo N, et al. (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11(4):317–370. https://doi.org/10.1007/s12072-017-9799-9 PubMedPubMedCentralCrossRef

15.

Tan CH, Low SC, Thng CH (2011) APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: a review. Int J Hepatol 2011:519783. https://doi.org/10.4061/2011/519783 PubMedPubMedCentralCrossRef

16.

Tang A, Bashir MR, Corwin MT, et al. (2018) Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 286(1):29–48. https://doi.org/10.1148/radiol.2017170554 PubMedCrossRef

17.

Cerny M, Bergeron C, Billiard JS, et al. (2018) LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology 288(1):118–128. https://doi.org/10.1148/radiol.2018171678 PubMedCrossRef

18.

International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2):658–664. https://doi.org/10.1002/hep.22709 CrossRef

19.

Coleman WB (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3(6):573–588PubMedCrossRef

20.

Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T (2001) Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 39(1):66–73PubMedCrossRef

21.

Park YN (2011) Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med 135(6):704–715. https://doi.org/10.1043/2010-0524-RA.1 PubMedCrossRef

22.

Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 272(3):635–654. https://doi.org/10.1148/radiol.14132361 PubMedPubMedCentralCrossRef

23.

Monzawa S, Omata K, Shimazu N, et al. (1999) Well-differentiated hepatocellular carcinoma: findings of US, CT, and MR imaging. Abdom Imaging 24(4):392–397PubMedCrossRef

24.

Li CS, Chen RC, Tu HY, et al. (2006) Imaging well-differentiated hepatocellular carcinoma with dynamic triple-phase helical computed tomography. Br J Radiol 79(944):659–665. https://doi.org/10.1259/bjr/12699987 PubMedCrossRef

25.

Van Beers BE, Pastor CM, Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57(2):421–429. https://doi.org/10.1016/j.jhep.2012.01.031 PubMedCrossRef

26.

Kitao A, Zen Y, Matsui O, et al. (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging–correlation with molecular transporters and histopathologic features. Radiology 256(3):817–826. https://doi.org/10.1148/radiol.10092214 PubMedCrossRef

27.

Kitao A, Matsui O, Yoneda N, et al. (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21(10):2056–2066. https://doi.org/10.1007/s00330-011-2165-8 PubMedCrossRef

28.

Kogita S, Imai Y, Okada M, et al. (2010) Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 20(10):2405–2413. https://doi.org/10.1007/s00330-010-1812-9 PubMedCrossRef

29.

Narita M, Hatano E, Arizono S, et al. (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44(7):793–798. https://doi.org/10.1007/s00535-009-0056-4 PubMedCrossRef

30.

Kim JW, Lee CH, Kim SB, et al. (2016) Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules. J Magn Reson Imaging . https://doi.org/10.1002/jmri.25493 CrossRefPubMedPubMedCentral

31.

Niendorf E, Spilseth B, Wang X, Taylor A (2015) Contrast enhanced MRI in the diagnosis of HCC. Diagnostics (Basel) 5(3):383–398. https://doi.org/10.3390/diagnostics5030383 CrossRef

32.

Tsuboyama T, Onishi H, Kim T, et al. (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging–correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255(3):824–833. https://doi.org/10.1148/radiol.10091557 PubMedCrossRef

33.

Kitao A, Matsui O, Yoneda N, et al. (2012) Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 265(3):780–789. https://doi.org/10.1148/radiol.12120226 PubMedPubMedCentralCrossRef

34.

Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN (2012) Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol 81(12):3877–3882. https://doi.org/10.1016/j.ejrad.2012.07.021 PubMedCrossRef

35.

Yamashita T, Kitao A, Matsui O, et al. (2014) Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 60(5):1674–1685. https://doi.org/10.1002/hep.27093 PubMedPubMedCentralCrossRef

36.

Ueno A, Masugi Y, Yamazaki K, et al. (2014) OATP1B3 expression is strongly associated with Wnt/beta-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 61(5):1080–1087. https://doi.org/10.1016/j.jhep.2014.06.008 PubMedCrossRef

37.

Kitao A, Matsui O, Yoneda N, et al. (2015) Hepatocellular carcinoma with beta-catenin mutation: imaging and pathologic characteristics. Radiology 275(3):708–717. https://doi.org/10.1148/radiol.14141315 PubMedCrossRef

38.

An C, Rhee H, Han K, et al. (2017) Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. Eur Radiol 27(6):2610–2618. https://doi.org/10.1007/s00330-016-4634-6 PubMedCrossRef

39.

Ojima H, Masugi Y, Tsujikawa H, et al. (2016) Early hepatocellular carcinoma with high-grade atypia in small vaguely nodular lesions. Cancer Sci 107(4):543–550. https://doi.org/10.1111/cas.12893 PubMedPubMedCentralCrossRef

40.

Motosugi U, Bannas P, Sano K, Reeder SB (2015) Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J Magn Reson Imaging 41(2):251–265. https://doi.org/10.1002/jmri.24712 PubMedCrossRef

41.

Sano K, Ichikawa T, Motosugi U, et al. (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261(3):834–844. https://doi.org/10.1148/radiol.11101840 PubMedCrossRef

42.

Schlageter M, Terracciano LM, D’Angelo S, Sorrentino P (2014) Histopathology of hepatocellular carcinoma. World J Gastroenterol 20(43):15955–15964. https://doi.org/10.3748/wjg.v20.i43.15955 PubMedPubMedCentralCrossRef

43.

Reynolds AR, Furlan A, Fetzer DT, et al. (2015) Infiltrative hepatocellular carcinoma: what radiologists need to know. Radiographics 35(2):371–386. https://doi.org/10.1148/rg.352140114 PubMedCrossRef

44.

Rosenkrantz AB, Lee L, Matza BW, Kim S (2012) Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. Clin Radiol 67(12):e105–111. https://doi.org/10.1016/j.crad.2012.08.019 PubMedCrossRef

45.

Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK (2003) Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 18(2):189–195. https://doi.org/10.1002/jmri.10336 PubMedCrossRef

46.

Park YS, Lee CH, Kim BH, et al. (2013) Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis. Magn Reson Imaging 31(7):1137–1142. https://doi.org/10.1016/j.mri.2013.01.011 PubMedCrossRef

47.

Kneuertz PJ, Demirjian A, Firoozmand A, et al. (2012) Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol 19(9):2897–2907. https://doi.org/10.1245/s10434-012-2336-0 PubMedPubMedCentralCrossRef

48.

Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M (2006) Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol 21(9):1470–1477. https://doi.org/10.1111/j.1440-1746.2006.04372.x PubMedCrossRef

49.

Lee JH, Choi MS, Gwak GY, et al. (2012) Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma. Dig Dis Sci 57(6):1698–1707. https://doi.org/10.1007/s10620-012-2075-x PubMedCrossRef

50.

Choi SY, Kim YK, Min JH, et al. (2018) Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging. Eur Radiol . https://doi.org/10.1007/s00330-017-5196-y PubMedCentralCrossRefPubMed

51.

Park MJ, Kim YK, Park HJ, Hwang J, Lee WJ (2013) Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 37(6):872–881. https://doi.org/10.1097/RCT.0b013e31829d44c1 PubMedCrossRef

52.

Chong YS, Kim YK, Lee MW, et al. (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67(8):766–773. https://doi.org/10.1016/j.crad.2012.01.004 PubMedCrossRef

53.

Agni RM (2016) Diagnostic histopathology of hepatocellular carcinoma: a case-based review. Semin Diagn Pathol . https://doi.org/10.1053/j.semdp.2016.12.008 PubMedCrossRef

54.

Arai T, Akita S, Sakon M, et al. (2014) Hepatocellular carcinoma associated with sarcoidosis. Int J Surg Case Rep 5(8):562–565. https://doi.org/10.1016/j.ijscr.2014.06.018 PubMedPubMedCentralCrossRef

55.

Chalasani P, Vohra M, Sheagren JN (2005) An association of sarcoidosis with hepatocellular carcinoma. Ann Oncol 16(10):1714–1715. https://doi.org/10.1093/annonc/mdi306 PubMedCrossRef

56.

Wong VS, Adab N, Youngs GR, Sturgess R (1999) Hepatic sarcoidosis complicated by hepatocellular carcinoma. Eur J Gastroenterol Hepatol 11(3):353–355PubMedCrossRef

57.

Ogata S, Horio T, Sugiura Y, et al. (2010) Sarcoidosis-associated hepatocellular carcinoma. Acta Med Okayama 64(6):407–410. https://doi.org/10.18926/AMO/41327 PubMedCrossRef

58.

Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A (1999) Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 160(5 Pt 1):1668–1672. https://doi.org/10.1164/ajrccm.160.5.9904045 PubMedCrossRef

59.

Romer FK, Hommelgaard P, Schou G (1998) Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients. Eur Respir J 12(4):906–912PubMedCrossRef

60.

Potretzke TA, Tan BR, Doyle MB, et al. (2016) Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS Analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 207(1):25–31. https://doi.org/10.2214/AJR.15.14997 PubMedCrossRef

61.

Shetty AS, Fowler KJ, Brunt EM, et al. (2014) Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 39(2):310–322. https://doi.org/10.1007/s00261-013-0069-6 PubMedCrossRef

62.

Sammon J, Fischer S, Menezes R, et al. (2018) MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging 18(1):8. https://doi.org/10.1186/s40644-018-0142-z PubMedPubMedCentralCrossRef

63.

de Campos RO, Semelka RC, Azevedo RM, et al. (2012) Combined hepatocellular carcinoma-cholangiocarcinoma: report of MR appearance in eleven patients. J Magn Reson Imaging 36(5):1139–1147. https://doi.org/10.1002/jmri.23754 PubMedCrossRef

64.

Horvat N, Nikolovski I, Long N, et al. (2018) Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdom Radiol (NY) 43(1):169–178. https://doi.org/10.1007/s00261-017-1261-x CrossRef

65.

Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273(1):30–50. https://doi.org/10.1148/radiol.14132362 PubMedPubMedCentralCrossRef

66.

Salomao M, Remotti H, Vaughan R, et al. (2012) The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43(5):737–746. https://doi.org/10.1016/j.humpath.2011.07.005 PubMedCrossRef

67.

Sanyal A, Poklepovic A, Moyneur E, Barghout V (2010) Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 26(9):2183–2191. https://doi.org/10.1185/03007995.2010.506375 PubMedCrossRef

68.

Streba LA, Vere CC, Rogoveanu I, Streba CT (2015) Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 21(14):4103–4110. https://doi.org/10.3748/wjg.v21.i14.4103 PubMedPubMedCentralCrossRef

69.

Koo HR, Park MS, Kim MJ, et al. (2008) Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. J Comput Assist Tomogr 32(5):745–749. https://doi.org/10.1097/RCT.0b013e3181591ccd PubMedCrossRef

70.

Maeda T, Adachi E, Kajiyama K, et al. (1996) Spindle cell hepatocellular carcinoma. A clinicopathologic and immunohistochemical analysis of 15 cases. Cancer 77(1):51–57. 10.1002/(SICI)1097-0142(19960101)77:1<51::AID-CNCR10>3.0.CO;2-7PubMedCrossRef

71.

Honda H, Hayashi T, Yoshida K, et al. (1996) Hepatocellular carcinoma with sarcomatous change: characteristic findings of two-phased incremental CT. Abdom Imaging 21(1):37–40PubMedCrossRef

72.

Hung Y, Hsieh TY, Gao HW, Chang WC, Chang WK (2014) Unusual computed tomography features of ruptured sarcomatous hepatocellular carcinoma. J Chin Med Assoc 77(5):265–268. https://doi.org/10.1016/j.jcma.2014.02.006 PubMedCrossRef

Titel: Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation
verfasst von: Hsien Min Low
Jin Young Choi
Cher Heng Tan
Publikationsdatum: 25.08.2018
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 2/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-018-1749-z

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation

Abstract

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Double contrast-enhanced ultrasound improves the detection and localization of occult lesions in the pancreatic tail: a initial experience report

Imaging features related with prognosis of hepatocellular carcinoma

Venetian blind shadowing on ultrasound

Dual-energy CT in the obese: a preliminary retrospective review to evaluate quality and feasibility of the single-source dual-detector implementation

Contrast- vs. non-contrast enhanced MR data sets for characterization of perianal fistulas

Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie